Placental Biomarkers and Pregnancy Outcomes

Abstract

Placental biomarkers have emerged as critical tools for the prediction and management of adverse pregnancy outcomes, including preeclampsia, fetal growth restriction, and preterm birth. This review synthesizes recent scientific evidence and clinical guidelines regarding the utility of placental biomarkers, elucidates their underlying mechanisms, and discusses practical implications for obstetric care. Emphasis is placed on the epidemiological significance, pathophysiological basis, risk stratification, diagnosis, and therapeutic strategies, as well as recent advances and future directions in the field. Clinicians and researchers will benefit from an integrated overview, highlighting the importance of biomarker-driven precision medicine in improving maternal and perinatal outcomes.

Introduction

The placenta is central to fetal development and maternal adaptation during pregnancy, functioning as the interface for nutrient, gas, and waste exchange. Disruptions in placental development and function underlie many adverse pregnancy outcomes. Recently, placental biomarkers molecules synthesized or regulated by placental tissues and detectable in maternal blood have gained recognition for their predictive and diagnostic utility in obstetrics. Understanding the evolving landscape of placental biomarker research offers opportunities to enhance early detection, risk stratification, and management of pregnancy complications, thus improving maternal and neonatal health worldwide.

Epidemiology / Disease Burden

Globally, complications such as preeclampsia, fetal growth restriction (FGR), and preterm birth contribute significantly to maternal and neonatal morbidity and mortality. Preeclampsia affects approximately 2–8% of pregnancies, while FGR occurs in up to 10% of gestations. Preterm birth, defined as delivery before 37 weeks of gestation, remains a leading cause of neonatal death and long-term morbidity. Early identification of women at risk is hampered by the nonspecificity of clinical symptoms and the late onset of phenotypic manifestations. Placental biomarkers represent a promising avenue to address these challenges and potentially reduce the disease burden through timely intervention.

Pathophysiology

The pathogenesis of adverse pregnancy outcomes frequently involves impaired placental development and function. Aberrations in trophoblast invasion, inadequate remodeling of spiral arteries, oxidative stress, and dysregulated angiogenic signaling are central to these disorders. Placental biomarkers such as soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), pregnancy-associated plasma protein-A (PAPP-A), and human chorionic gonadotropin (hCG) mirror these pathophysiological changes. For example, imbalance between pro-angiogenic (PlGF) and anti-angiogenic (sFlt-1) factors is a hallmark of preeclampsia and FGR, reflecting placental hypoxia and endothelial dysfunction. Understanding the molecular basis of these biomarkers is essential for interpreting their clinical significance.

Risk Factors

Multiple maternal, fetal, and placental factors modulate the risk of adverse outcomes and influence biomarker profiles. Maternal risk factors include advanced age, obesity, hypertension, diabetes, pre-existing renal or autoimmune disease, and history of prior placental dysfunction. Assisted reproductive technologies, multiple gestation, and certain genetic polymorphisms also contribute to placental insufficiency. Environmental and lifestyle factors, such as smoking and high-altitude residence, may affect placental angiogenesis and biomarker expression. Stratifying patients based on these risk factors enhances the utility of biomarker-based screening and surveillance strategies.

Clinical Features

Adverse pregnancy outcomes often present with subtle or nonspecific clinical features, making early recognition challenging. Preeclampsia is classically characterized by new-onset hypertension and proteinuria after 20 weeks of gestation, but may also manifest with headaches, visual disturbances, and epigastric pain. FGR is suspected when fetal size lags behind gestational age, often detected through serial ultrasounds. Preterm birth may occur spontaneously or as a consequence of medical intervention for maternal or fetal indications. Placental biomarker trends can precede clinical manifestations by weeks, offering a window for early intervention.

Diagnosis

Conventional diagnostic approaches rely on clinical assessment and imaging, but these can be limited by subjectivity and late detection. Integration of placental biomarkers into diagnostic algorithms has improved predictive accuracy. The sFlt-1/PlGF ratio is now widely used to assess risk and guide management in women with suspected preeclampsia, with validated cutoffs enhancing diagnostic confidence. First-trimester screening combining PAPP-A, free β-hCG, and uterine artery Doppler improves early detection of FGR and preeclampsia. Serial biomarker monitoring provides dynamic risk assessment and supports individualized care pathways.

Treatment & Management

Currently, definitive treatment for many placental disorders remains delivery; however, biomarker-guided management offers opportunities to optimize timing and intensity of interventions. For preeclampsia, close surveillance based on sFlt-1/PlGF ratios can inform decisions about hospitalization, corticosteroid administration, and delivery planning. In cases of suspected FGR, abnormal biomarker profiles prompt enhanced fetal monitoring and consideration of early delivery if fetal compromise is detected. Aspirin prophylaxis is recommended for high-risk women identified by first-trimester screening. Ongoing research is evaluating targeted therapies that modulate angiogenic pathways or ameliorate placental dysfunction.

Recent Advances / Emerging Therapies

Recent advances in placental biomarker research include multiplex assays, integration with machine learning algorithms, and discovery of novel markers such as microRNAs and cell-free fetal DNA. Liquid biopsy approaches facilitate noninvasive monitoring of placental health throughout gestation. Emerging therapies targeting angiogenic imbalance such as recombinant PlGF or anti-sFlt-1 agents are in preclinical or early-phase clinical trials. Personalized medicine approaches, leveraging biomarker profiles and risk modeling, hold promise for more precise, patient-centric care. The ongoing expansion of multicenter biobanks and collaborative research networks is accelerating biomarker validation and clinical translation.

Guideline Recommendations

Leading organizations, including the International Society for the Study of Hypertension in Pregnancy (ISSHP) and the American College of Obstetricians and Gynecologists (ACOG), now endorse the use of placental biomarkers to support diagnosis and management of preeclampsia and related disorders. Recommendations emphasize the role of first-trimester combined screening for risk stratification and the use of sFlt-1/PlGF ratio for triage and surveillance in symptomatic women. Guideline-driven protocols are associated with improved maternal and perinatal outcomes, highlighting the importance of evidence-based implementation in clinical practice.

Conclusion

Placental biomarkers have transformed the landscape of obstetric care by enhancing early detection, risk stratification, and management of adverse pregnancy outcomes. A growing body of evidence supports their integration into routine clinical practice, with guideline recommendations now reflecting their utility. Ongoing advances in biomarker discovery, assay technology, and therapeutic targeting are poised to further improve outcomes for mothers and infants. Continued research, interdisciplinary collaboration, and equitable access are essential for realizing the full potential of placental biomarkers in optimizing pregnancy outcomes worldwide.